TWI268921B - A process for preparing (2R)-2-propyloctanoic acid - Google Patents
A process for preparing (2R)-2-propyloctanoic acid Download PDFInfo
- Publication number
- TWI268921B TWI268921B TW089102580A TW89102580A TWI268921B TW I268921 B TWI268921 B TW I268921B TW 089102580 A TW089102580 A TW 089102580A TW 89102580 A TW89102580 A TW 89102580A TW I268921 B TWI268921 B TW I268921B
- Authority
- TW
- Taiwan
- Prior art keywords
- octanoic acid
- acid
- propenyl
- optical purity
- propynyl
- Prior art date
Links
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 title claims abstract 8
- 238000004519 manufacturing process Methods 0.000 title description 4
- 230000003287 optical effect Effects 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 23
- RXAINMDCYOMAHC-SNVBAGLBSA-N (2s)-2-prop-2-enyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CC=C RXAINMDCYOMAHC-SNVBAGLBSA-N 0.000 claims abstract description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- DUQSBRQHALCSLC-SNVBAGLBSA-N (2s)-2-prop-2-ynyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CC#C DUQSBRQHALCSLC-SNVBAGLBSA-N 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 20
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 12
- 238000006722 reduction reaction Methods 0.000 claims description 12
- DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 claims description 9
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 7
- JUWSSMXCCAMYGX-UHFFFAOYSA-N gold platinum Chemical compound [Pt].[Au] JUWSSMXCCAMYGX-UHFFFAOYSA-N 0.000 claims description 4
- DUQSBRQHALCSLC-UHFFFAOYSA-N 2-prop-2-ynyloctanoic acid Chemical compound CCCCCCC(C(O)=O)CC#C DUQSBRQHALCSLC-UHFFFAOYSA-N 0.000 claims description 3
- YCYMCMYLORLIJX-UHFFFAOYSA-N 2-propyloctanoic acid Chemical compound CCCCCCC(C(O)=O)CCC YCYMCMYLORLIJX-UHFFFAOYSA-N 0.000 claims description 3
- -1 alkynyl octanoic acid Chemical compound 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- KDWPJVXNULWVPC-UHFFFAOYSA-N 2-prop-1-ynyloctanoic acid Chemical compound CCCCCCC(C(O)=O)C#CC KDWPJVXNULWVPC-UHFFFAOYSA-N 0.000 claims 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 230000007488 abnormal function Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 238000006317 isomerization reaction Methods 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229960002446 octanoic acid Drugs 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XOBKSJJDNFUZPF-UHFFFAOYSA-N Methoxyethane Chemical compound CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 description 1
- MDWDOBYYOVBFNK-UHFFFAOYSA-N 2-propan-2-ylideneoctanoic acid Chemical compound CCCCCCC(=C(C)C)C(O)=O MDWDOBYYOVBFNK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- SQKPPECKDHASCX-UHFFFAOYSA-N butylazanium tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].CCCC[NH3+].CCCC[NH3+].CCCC[NH3+].CCCC[NH3+] SQKPPECKDHASCX-UHFFFAOYSA-N 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/42—Platinum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J21/00—Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
- B01J21/18—Carbon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/36—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Description
1268921 A7 五、發明說明(2) (2R) 一 2—丙基辛酸的製造方法,如特開+ 8-291106 號說明書中記載’由消旋體2—(2—丙炔基)辛酸與光學活 性體的胺鹽經由光學解析而分離出光學活性鹽,用酸處理 後、將所得光學活性之(2S)_2—(2_丙稀基)辛酸還原的 方法。又,W〇99/58513號說明書亦報導將&(2_丙稀 基)辛酸或2S — (2 —丙炔基)辛酸還原之方法 〜上述兩說明書中的還原反應’以用接觸還原法比較適 宜'詳言之,是記載在有機溶劑中,於氣氣園繞下,使用 觸媒(鈀碳、鈀、白金、氧化白金、鎳等),於〇至抓間 進行還原反應。其具體例在各個實施例中記載使用把碳觸 媒。 然而,此等還原方法,於反應中會產生異構化現象, 除了目的化合物以外’亦會副產出數%的光學異構物s 體。 [發明說明] 為了解決S體副生成問題 後’結果發現還原反應的觸媒 時’幾乎不會產生異構化現象 的化合物’而完成本發明。即 U物不會異構化且純度高,因而可以提供作為安全的醫藥 品° 使用白金碳而能得到不會產生異構化、光學純度高的 目的化口物之事實’到目月5為止完全未被發現,此次的檢 討為首次發現者。 本紙張尺度適用中國國家標準(CNS;)A4規格⑽x 297公复丁 2 311172 請 先 閱 讀 背 面 之 注 意 事 項 再 填 寫 本 頁
訂 本發明人經過刻意的檢討 若改用白金碳來代替把碳 可以獲得光學純度高的目 依據本發明的方法,因化 4 1268921 Α7 Β7 經濟部智慧財產局員工消費合作社印製 3 五、發明說明(3) 起始物質的(2S) - 2 - Ο 工& ^ 、)2 (2〜丙炔基)辛酸及(2S)_2_(2 〜丙烯基)辛酸為悉知化合物 σ物例如,記載於W099/58513 說明書。 本發明方法中,起始物質的還原反應,係在有機溶劑 [例如、醋酸乙酷、四氫呋喃、二嗜垸、:甲氧乙燒、乙喊、 二苯醚、甲醇、乙醇、異丙醇、苯、甲苯、二甲苯、ημρα、 ,甲基甲酿胺、二甲基味唾咬、此等之混合溶劑等]中,於 氧氣圍繞下,使用白金碳觸媒太 ^ ^在〇至^ C溫度範圍間進 行反應。 白金碳觸媒可從市面上購桿太 丄碼件,本發明中所用者即為 售品。 此白金碳觸媒使用量,對屌料 、 玎屌料而吕,以0.1〜20%範圍 為宜,但以0.1〜10%較好。 依據本發明方法不會起異構化反應,與習知方法㈣ 後作觸媒㈣原法)相比,可得光學純度高的—2 基辛酸。 Θ 即’以習知方法製得目的化合物味 G 口物時,由於部分會起異 構化現象,而使光學純度下降,彳 、 1一便用本發明方法,則可 得到幾乎不會起異構化之高純度目的化合物。 、 下表表示使用本發明方法與習知方 々次(後述的比較例 及比較例2所記載的方法)所製得 叼化口物之光學钟 本紙張尺度翻中國國家標準(CNS)A4規格(210 X 297公釐) 311172 J - ---------'--:-----------訂---------^^^1 (請先閱讀背面之注意事項再填寫本頁) 1268921 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(4) 表 1 起始原料 還原方法(觸媒) 起始原料的光學純度 目的化物的光學純度 (2S)-2-(2-丙烯基) 辛酸 本發明方法 (白金碳) 99.8%e.e. 99.4% e.e. 比較例1 (鈀碳) 99.0%e.e. 95.2%e.e. (2S>2<2-丙炔基) 辛酸 本發明方法 (白金碳) 99.9%e.e. 99.3%e.e. 比較例2 (鈀碳) 99.9%e.e. 97.1%e.e. 由表可知,以本發明方法所得到之目的化合物的光學 純度高、且保持高水準,相對的,以比較例方法所得到的 目的化合物之光學純度大幅下降。 具體而言,由比較例方法所得到之目的化合物的光學 純度,分別比起始原料的光學純度下降3.8%及2.8%,相 對於此,本發明方法所得到之目的化合物的光學純度僅僅 下降0.4%及0.6%,且保持目的化合物的高光學純度。 如前述般,於醫藥品中,有副生成物的含有率佔有相 當大的意義。從此觀點來看,能抑制副生成物的生成比率 低、保持高光學純度即具有畫時代的成果。依本發明方法, 可以完全預測到能得到如此的效果。 因此,依據本發明方法所得的目的化合物不會起異構 化現象,可得光學純度較高的化合物,是以,本發明為非 常優異的製造方法。 [發明實施的最佳形態] --------訂---------. (請先閱讀背面之注意事項再填寫本頁)
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 4 311172
經濟部智慧財產局員工消費合作社印製 工268921 ' , Α7 五、發明說明(5) 以下,列舉實施例與比較例來具體說明本發明,但本 發明的範圍並不限定於該等實施例。 复例1 (2S)—2 —(2—丙稀基)辛酸%己胺鹽
於 N — (2S — (2—丙稀基)辛醯基)一(is)—(_)_2 1〇 棒腦確醯胺(W099/58513號發明說明書中記載的化合物) (3〇克)之二甲氧乙烷(DME) (3公升)溶液申,在_5至_ 1〇 C間、加入2 —甲基一 2 — 丁烯(165克)及過氧化氫(3〇%; Π7克)。然後於30分鐘内、—10至(rc間、將氫氧化四(正 一 丁基)銨(40%,· 1015克)之DME (749毫升)溶液滴入該溶 液中。混合溶液溫度升到0°c後、攪拌3小時,隨後將亞 硫酸鈉水溶液(198.5克/1050毫升)於1〇分鐘内滴入此反 應溶液中。升溫到室溫後,再攪拌30分鐘。在此反應溶液 中,加入鹽酸水溶液(1.5公升/水3公升),接著以第三丁 基甲基醚(3公升)萃取,有機層以草酸水溶液(151克/水 1·5公升)、水(1.5公升χ3次)及飽和食鹽水(2公升)洗淨 後,濃縮之。殘渣中加入庚烷(3〇〇毫升)、再度濃縮之。殘 盧中加入庚烧(600毫升)、過濾掉不溶物、濃縮濾液,殘 渣中加入醋酸乙酯(1公升)與環己胺(7〇 2克)並加熱,放冷 搁置一晚。溶液用冰水冷卻一小時後、過濾出結晶、乾燥、 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 311172 C請先閱讀背面之注意事項再填寫本頁}
5 1268921 A7 B7 五、發明說明(6) 可得標題化合物(145克;收率65%) (2S)—2—(2—丙浠基)辛酸
OH 於參考例1所製得之化合物(140克)中,加入正己 醋酸乙酯(4/1 ; 2790毫升)及2N鹽酸(270毫升),授拌3〇 分鐘後,除去水層。有機層用水(690毫升x 3次)洗淨,然 後用2.6N氫氧化鈉水溶液(750毫升)萃取。水層用正己烷j 醋酸乙醋(4/1 ; 2790毫升X 2次)洗淨,水層中加入2N鹽 酸(990毫升)、用正己烷/醋酸乙酯(4/1 ; 279〇毫升)萃 取,有機層用水(690毫升X 3次)、飽和食鹽水洗淨後、濃 縮之,製得標題化合物(89克;收率98%)。 光學純度(由氣相層析分析測定):99 8%e e。 實施例1 由白金碳觸媒製造(2R) - 2 —丙基辛酸 烷/ (請先閱讀背面之注意事項再填寫本頁) 經 濟 部 智 慧 財 產 局 消 費 合 作 社 印 製
5%白金碳(44含濕%) (9·91克)中,加入參考例2所 製得化合物(87克)之異丙醇(2·17公升)溶液中,在氫氣加 壓下(5公斤/平方公分)、於30°C下 '進行接觸還原4小 時。過濾反應液、濃縮濾液。殘渣中加入正己烧/醋酸乙 _本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 311172 1268921
五、發明說明(υ 烷/醋酸乙酯(215公升/43公 ^ ... X 升)各解殘留物,加入2Ν氫氧 化鈉水溶液(72公升)萃取, ^ r ^ 0 1 . v , 出的水相中加入正己烧/醋 酸乙S日(215公升/43公升)撸扯 v . ^ a 早。混合液中加入濃鹽酸(13 公升)。有機層用水洗3次、你$ a 飽和食鹽水洗1次,然後用盔 水硫酸鎂乾燥,濃縮之,得 …、 己、甘 、粗製的標題化合物(12.25公 斤)。蒸餾粗製物,從主餾物挥 件到有下述物性值的標題化合 物(8399.7 克;收率 63.2%)。 光學純度(由HPLC測定” 97 14%e e [產業利用性] 依照本發明的方法,可以高光學純度得到可作為醫藥 品的(2R)- 2-丙基辛酸’不會混有引起副作用的不純物, 可提供作為安全的醫藥品。 經濟部智慧財產局員工消費合作社印製
本紙張尺度_巾_家鮮(cns)A4祕⑽x^7iT 9 311172
Claims (1)
1268921
|91〇258〇號專利申請寒 《 請專利範圍修正本,U7 —u| ... ….一一.— J , ▲… (95年7月21曰) . 造高光學純度(2R)〜2-丙基辛酸之方法,其 係使用白金碳作為觸媒,於有機溶劑中,氫氣下於0 至6 0 C溫度下栋「9 q。 使(2S)~ 2〜(2一丙炔基)辛酸或(2S) — 2 —(2—丙烯基)辛酸進行還原反應。 2 ·如申請專利範圍第彳馆 固弟1項之方法,其特徵是使(2S) — 2 一(2—丙炔基)辛酸進行還原反應。 3 ·如申請專利範圍第1頂 固乐項之方法,其特徵是使(2S) — 2 一(2—丙烯基)辛酸進行還原反應。 4· 一種( 2R) -2-丙基辛酸,其光學純度超過99%ee者。 5·如申明專利範圍第4項之(2R) -2-丙基辛酸,係使 用白金碳將選自(2S) _2_ (2-丙炔基)辛酸及(2S) _2_ (2-丙烯基)辛酸之化合物還原而得者。 6·如申請專利範圍第4項之(2R) _2_丙基辛酸,係具 有光學純度為99.3%ee以上者。 經濟部中央標準局員Η福利委員會印製 7·如申請專利範圍第6項之(2R) _2_丙基辛酸,係使 用白金碳將選自(2S) -2- (2-丙炔基)辛酸及(2S) -2- ( 2-丙烯基)辛酸之化合物還原而得者。 8· —種光學純度光學純度超過99%ee之(2R)—2—丙基 辛酸’其係使用白金石炭作為觸媒,使(2;§) 一 2 —(2 — 丙炔基)辛酸或(2S)— 2—(2 —丙烯基)辛酸進行還原 反應而得者。 本紙張尺度適用中國國家標準(CNS) Α4规格(210 X 297公釐) 1 311172(修正版) 1268921 ^ _________H3_ 9. 一種光學純度超過99.3%ee之(2R) — 2 —丙基辛酸, 其係使用白金碳作為觸媒,使(2S) — 2— (2—丙炔基) 辛酸或(2S) — 2 — (2 —丙烯基)辛酸進行還原反應而得 者。 1 0 · —種星狀細胞機能異常引起之神經性疾病之治療及/ 或預防劑,係包含光學純度超過99%ee之(2R) — 2 — 丙基辛酸者。 經濟部中央標準局員工福利委員會印製 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 2 311172(修正版)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3975899 | 1999-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI268921B true TWI268921B (en) | 2006-12-21 |
Family
ID=12561862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089102580A TWI268921B (en) | 1999-02-18 | 2000-02-16 | A process for preparing (2R)-2-propyloctanoic acid |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6608221B1 (zh) |
| EP (3) | EP1714956A1 (zh) |
| JP (2) | JP4752989B2 (zh) |
| KR (1) | KR100666423B1 (zh) |
| CN (4) | CN1907938A (zh) |
| AT (1) | ATE359256T1 (zh) |
| AU (1) | AU776927B2 (zh) |
| BR (1) | BR0008261A (zh) |
| CA (1) | CA2364308C (zh) |
| DE (1) | DE60034316T2 (zh) |
| ES (1) | ES2283287T3 (zh) |
| HU (1) | HUP0200358A3 (zh) |
| MX (1) | MXPA01008241A (zh) |
| NO (1) | NO20013971D0 (zh) |
| NZ (1) | NZ513569A (zh) |
| RU (1) | RU2297406C2 (zh) |
| TW (1) | TWI268921B (zh) |
| WO (1) | WO2000048982A1 (zh) |
| ZA (1) | ZA200106500B (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI268921B (en) * | 1999-02-18 | 2006-12-21 | Ono Pharmaceutical Co | A process for preparing (2R)-2-propyloctanoic acid |
| JP4178405B2 (ja) | 2001-07-18 | 2008-11-12 | 小野薬品工業株式会社 | 脳虚血疾患治療剤 |
| JP2005298334A (ja) * | 2001-12-19 | 2005-10-27 | Ono Pharmaceut Co Ltd | 新規な中間体化合物およびそれを用いる化合物の製造方法 |
| NZ546231A (en) | 2003-10-03 | 2009-09-25 | Ono Pharmaceutical Co | Drug containing (2R)-2-propyloctanoic acid as the active ingredient |
| US7928143B2 (en) * | 2003-10-03 | 2011-04-19 | Ono Pharmaceutical Co., Ltd. | Method for preventing and/or treating neurodegenerative diseases |
| EP1669066A4 (en) * | 2003-10-03 | 2009-04-29 | Ono Pharmaceutical Co | TRANSFUSION PREPARATION CONTAINING (2R) -2-PROPYLOCTANOIC ACID AS ACTIVE INGREDIENT |
| US7820715B2 (en) | 2004-04-28 | 2010-10-26 | Ono Pharmaceutical Co., Ltd. | Crystal comprising (2R)-2-propyloctanoic acid and amine |
| WO2006055404A2 (en) * | 2004-11-16 | 2006-05-26 | Merck & Co., Inc. | Compounds for targeting mechanisms implicated in the progression of stroke |
| JPWO2006075596A1 (ja) * | 2005-01-13 | 2008-06-12 | 株式会社クラレ | 2−アリルカルボン酸化合物の製造方法 |
| EP1859795A4 (en) | 2005-03-15 | 2008-06-04 | Ono Pharmaceutical Co | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES |
| WO2007000970A1 (ja) | 2005-06-27 | 2007-01-04 | Ono Pharmaceutical Co., Ltd. | 疼痛治療剤 |
| EP1938814A4 (en) | 2005-10-18 | 2009-06-03 | Ono Pharmaceutical Co | PHARMACEUTICAL PRODUCT FOR PROTECTING MOTOR NERVE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS |
| EP1974727A4 (en) | 2005-12-22 | 2009-12-09 | Ono Pharmaceutical Co | THERAPEUTIC AGENT AGAINST ACUTE CEREBRALINE INFARC |
| US20090118542A1 (en) * | 2006-02-16 | 2009-05-07 | Shigeya Yamazaki | Process for Production of Optically Active Carboxlic Acid Compound |
| US20090325862A1 (en) * | 2006-05-04 | 2009-12-31 | Christian Steinkuhler | Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration |
| CN102417445B (zh) * | 2011-11-05 | 2013-11-13 | 中国科学院山西煤炭化学研究所 | 一种由马来酸合成丁二酸的方法 |
| CN102675166B (zh) * | 2012-05-11 | 2014-03-26 | 山东齐都药业有限公司 | 用于制备2-丙基庚酸的新中间体、其制备方法及2-丙基庚酸的制备方法 |
| CN102786407B (zh) * | 2012-08-15 | 2014-04-16 | 湖北大学 | 一种制备(2r)-2-丙基辛酸的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2317019A1 (de) | 1972-04-27 | 1973-11-08 | Upjohn Co | Neue 4,5-didehydro-prostaglandine |
| JPH0672123B2 (ja) * | 1986-08-21 | 1994-09-14 | セントラル硝子株式会社 | トリフルオロメチル基を有するシクロヘキサンカルボン酸の製造方法 |
| JP2868183B2 (ja) * | 1988-02-29 | 1999-03-10 | 株式式社三和化学研究所 | 光学活性を有する4−オキソ−1−ベンゾピラン−2−カルボン酸誘導体の製法、その合成用中間体並びに該中間体の製法 |
| US5202474A (en) * | 1989-06-22 | 1993-04-13 | Monsanto Company | Asymmetric catalytic hydrogenation of α-arylpropenoic acids |
| TW248552B (zh) | 1993-06-01 | 1995-06-01 | Onoda Yakuhin Kogyo Kk | |
| JP3032447B2 (ja) * | 1995-04-24 | 2000-04-17 | 小野薬品工業株式会社 | 光学活性な2−プロピルオクタン酸の製造方法 |
| JP3084345B2 (ja) * | 1995-04-26 | 2000-09-04 | 小野薬品工業株式会社 | 光学活性な2−プロピルオクタン酸の製造方法 |
| TW509672B (en) * | 1998-05-12 | 2002-11-11 | Ono Pharmaceutical Co | Novel intermediate compounds and processes for the production of optical active octanoic acid derivatives |
| TWI268921B (en) * | 1999-02-18 | 2006-12-21 | Ono Pharmaceutical Co | A process for preparing (2R)-2-propyloctanoic acid |
| US7820715B2 (en) * | 2004-04-28 | 2010-10-26 | Ono Pharmaceutical Co., Ltd. | Crystal comprising (2R)-2-propyloctanoic acid and amine |
-
2000
- 2000-02-16 TW TW089102580A patent/TWI268921B/zh not_active IP Right Cessation
- 2000-02-17 BR BR0008261-9A patent/BR0008261A/pt not_active Application Discontinuation
- 2000-02-17 HU HU0200358A patent/HUP0200358A3/hu unknown
- 2000-02-17 CN CNA2006101002245A patent/CN1907938A/zh active Pending
- 2000-02-17 KR KR1020017010357A patent/KR100666423B1/ko not_active Expired - Fee Related
- 2000-02-17 CA CA002364308A patent/CA2364308C/en not_active Expired - Fee Related
- 2000-02-17 WO PCT/JP2000/000900 patent/WO2000048982A1/ja not_active Ceased
- 2000-02-17 MX MXPA01008241A patent/MXPA01008241A/es active IP Right Grant
- 2000-02-17 EP EP06012511A patent/EP1714956A1/en not_active Withdrawn
- 2000-02-17 EP EP00904007A patent/EP1153910B1/en not_active Expired - Lifetime
- 2000-02-17 AU AU25730/00A patent/AU776927B2/en not_active Ceased
- 2000-02-17 NZ NZ513569A patent/NZ513569A/xx not_active IP Right Cessation
- 2000-02-17 RU RU2001125501/04A patent/RU2297406C2/ru active
- 2000-02-17 EP EP06012510A patent/EP1721882A1/en not_active Withdrawn
- 2000-02-17 CN CNA2006100997275A patent/CN101100422A/zh active Pending
- 2000-02-17 CN CNB008040133A patent/CN1183082C/zh not_active Expired - Fee Related
- 2000-02-17 ES ES00904007T patent/ES2283287T3/es not_active Expired - Lifetime
- 2000-02-17 AT AT00904007T patent/ATE359256T1/de not_active IP Right Cessation
- 2000-02-17 CN CNB2004100927127A patent/CN100430364C/zh not_active Expired - Fee Related
- 2000-02-17 JP JP2000599723A patent/JP4752989B2/ja not_active Expired - Fee Related
- 2000-02-17 DE DE60034316T patent/DE60034316T2/de not_active Expired - Lifetime
- 2000-02-17 US US09/890,651 patent/US6608221B1/en not_active Expired - Fee Related
-
2001
- 2001-08-07 ZA ZA200106500A patent/ZA200106500B/en unknown
- 2001-08-15 NO NO20013971A patent/NO20013971D0/no not_active Application Discontinuation
-
2010
- 2010-05-20 JP JP2010116000A patent/JP5343925B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI268921B (en) | A process for preparing (2R)-2-propyloctanoic acid | |
| JPWO2000048982A1 (ja) | (2r)−2−プロピルオクタン酸の製造方法 | |
| HRP20000473A2 (en) | Novel process for preparing a ketamine | |
| JPS59204142A (ja) | ヘキサフルオロイソプロピルアルコ−ルの製造法 | |
| US20040110988A1 (en) | Catalyst to improve the colour stability of N,N-dialkylalkanolamines | |
| TW570918B (en) | Process for purifying 2-chloro-5-chloromethylthiazole | |
| JP3885497B2 (ja) | 1,2,4−ブタントリオールの製造方法 | |
| JPWO1996020189A1 (ja) | カルボン酸誘導体の製造法 | |
| US20220289649A1 (en) | Method for producing alkane compound | |
| JP4288451B2 (ja) | 1,1,1,3,3,3−ヘキサフルオロプロパン−2−オールの製造方法 | |
| Osawa et al. | Enantio-differentiating hydrogenation of methyl acetoacetate over fine nickel powder with in situ modification | |
| CA1039306A (en) | Preparation of optically active allethrolone via allethronyl acid phthalate | |
| CN112661586A (zh) | 一种3,3-二甲基-1-丁炔的制备方法 | |
| TW401421B (en) | A method of asymmeric synthezing of optically active peptides | |
| JPS63275573A (ja) | ピペリジンの合成方法 | |
| JP4314602B2 (ja) | 光学活性3−ヒドロキシピロリジン誘導体の製造方法 | |
| JP3904916B2 (ja) | フッ素を含有する脂環式ジアミン化合物の製造方法 | |
| GB667708A (en) | Improvements in or relating to preparation of catalytic and adsorbent magnesia-containing materials | |
| JPS63290851A (ja) | アルキルアミノアセタ−ル類の製造法 | |
| JPS5951958B2 (ja) | ハイドロキノンの製造法 | |
| JPS598254B2 (ja) | α−レゾルシン酸の製造法 | |
| JP4687849B2 (ja) | 高純度ジイソプロピルエーテルおよびその製法 | |
| JPH09143158A (ja) | 2−アルキルインドリンの製造方法 | |
| JPS63264567A (ja) | 2,3−ジメチルインドリンの製造方法 | |
| CA3108358A1 (en) | Preparation method for (1r,3s)-3-amino-1-cyclopentanol and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |